NO20062385L - Preparat for behandling av interferonresistente tumorer - Google Patents

Preparat for behandling av interferonresistente tumorer

Info

Publication number
NO20062385L
NO20062385L NO20062385A NO20062385A NO20062385L NO 20062385 L NO20062385 L NO 20062385L NO 20062385 A NO20062385 A NO 20062385A NO 20062385 A NO20062385 A NO 20062385A NO 20062385 L NO20062385 L NO 20062385L
Authority
NO
Norway
Prior art keywords
interferon
treatment
resistant tumors
preparation
recombinant vectors
Prior art date
Application number
NO20062385A
Other languages
English (en)
Inventor
William F Benedict
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of NO20062385L publication Critical patent/NO20062385L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for behandlingen av interferonresistente tumorer via anvendelsen av rekombinante vektorer som koder for interferontyper. Spesielt er det bemerket at interferontyper som blir tilveiebrakt ved rekombinante vektorer innehar egenskaper som ikke er assosiert med de rekombinant produserte interferonproteiner. Foreliggende oppfinnelse tilveiebringer ytterligere preparater som er nyttige i behandlingen av interferonresistente tumorer ved å benytte rekombinante vektorer som koder for interferoner.
NO20062385A 2003-12-10 2006-05-24 Preparat for behandling av interferonresistente tumorer NO20062385L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52852503P 2003-12-10 2003-12-10
PCT/US2004/041307 WO2005058368A1 (en) 2003-12-10 2004-12-10 Methods and compositions for treatment of interferon-resistant tumors

Publications (1)

Publication Number Publication Date
NO20062385L true NO20062385L (no) 2006-09-05

Family

ID=34699875

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062385A NO20062385L (no) 2003-12-10 2006-05-24 Preparat for behandling av interferonresistente tumorer

Country Status (17)

Country Link
US (7) US7691822B2 (no)
EP (2) EP1691844B1 (no)
JP (2) JP4801594B2 (no)
KR (1) KR101163248B1 (no)
CN (1) CN1893981B (no)
AT (1) ATE502654T1 (no)
AU (1) AU2004298991A1 (no)
BR (1) BRPI0417451A (no)
CA (1) CA2548100C (no)
DE (1) DE602004031973D1 (no)
ES (1) ES2363912T3 (no)
HK (1) HK1095525A1 (no)
IL (1) IL175820A0 (no)
NO (1) NO20062385L (no)
SG (2) SG133594A1 (no)
WO (1) WO2005058368A1 (no)
ZA (1) ZA200604640B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
CA2470999C (en) * 2001-12-20 2017-02-21 Schering-Plough Corporation Syn3 compositions and methods
NZ543970A (en) * 2003-06-04 2008-09-26 Canji Inc Methods and compositions for interferon therapy
SG133594A1 (en) * 2003-12-10 2007-07-30 Canji Inc Methods and compositions for treatment of interferon-resistant tumors
WO2006065827A2 (en) 2004-12-13 2006-06-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
US20070249043A1 (en) * 2005-12-12 2007-10-25 Mayall Timothy P Adenoviral expression vectors
EP2001502A1 (en) * 2006-03-31 2008-12-17 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
RU2530555C2 (ru) 2008-04-17 2014-10-10 ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН Стимуляция иммунного ответа энантиомерами катионных липидов
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3416727A4 (en) * 2016-02-15 2019-10-09 FKD Therapies Limited, IMPROVED INTERFERON THERAPY
US11311487B2 (en) 2016-04-14 2022-04-26 Trizell Ltd. Viral vector stabilization
CN111655238A (zh) * 2017-12-05 2020-09-11 Pds生物科技公司 用于刺激i型干扰素基因的包括阳离子脂质的方法和组合物
CN111363726A (zh) * 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用
US20200222477A1 (en) * 2019-01-10 2020-07-16 Trizell Ltd. Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer
KR20230013021A (ko) 2020-03-19 2023-01-26 트리젤 엘티디. 온도-반응성 바이러스 저장 시스템
CN115666618A (zh) * 2020-03-30 2023-01-31 崔泽尔有限公司 用于治疗癌症的组合物和方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5618711A (en) * 1986-08-22 1997-04-08 Hoffmann-La Roche Inc. Recombinant expression vectors and purification methods for Thermus thermophilus DNA polymerase
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5120316A (en) 1990-09-28 1992-06-09 Akzo N.V. Urethral catheter and catheterization process
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
EP0804076A4 (en) * 1994-10-19 1998-10-21 Genetic Therapy Inc GENTHERAPY THROUGH SIMULTANEOUS AND REPEATED ADMINISTRATION OF ADENOVIRUS AND IMMUNE SUPPRESSIVES
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
WO1997005209A1 (en) 1995-07-28 1997-02-13 Kohne David E Method for enhancing chemiluminescence
US20040014709A1 (en) 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
ZA979295B (en) * 1996-10-18 1998-04-20 Canji Inc Methods and compositions for delivery and expression of interferon-Ó nucleic acids.
US6210969B1 (en) * 1999-04-28 2001-04-03 Coulter International Corp. Composition and method for differentiation of basophil and eosinophil subpopulations of leukocytes in blood
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
CA2470999C (en) 2001-12-20 2017-02-21 Schering-Plough Corporation Syn3 compositions and methods
WO2003073998A2 (en) * 2002-03-02 2003-09-12 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
NZ543970A (en) * 2003-06-04 2008-09-26 Canji Inc Methods and compositions for interferon therapy
BRPI0410915A (pt) 2003-06-04 2006-06-27 Canji Inc composição farmacêutica, método para fornecer um interferon a um sujeito mamìfero, e, kit
SG133594A1 (en) 2003-12-10 2007-07-30 Canji Inc Methods and compositions for treatment of interferon-resistant tumors
US20070249043A1 (en) 2005-12-12 2007-10-25 Mayall Timothy P Adenoviral expression vectors

Also Published As

Publication number Publication date
US9439977B2 (en) 2016-09-13
BRPI0417451A (pt) 2007-04-10
IL175820A0 (en) 2006-10-05
WO2005058368A1 (en) 2005-06-30
US20050287119A1 (en) 2005-12-29
ES2363912T3 (es) 2011-08-19
SG133594A1 (en) 2007-07-30
JP4801594B2 (ja) 2011-10-26
ATE502654T1 (de) 2011-04-15
CA2548100A1 (en) 2005-06-30
EP1691844A1 (en) 2006-08-23
US20200164091A1 (en) 2020-05-28
ZA200604640B (en) 2007-04-25
AU2004298991A1 (en) 2005-06-30
HK1095525A1 (en) 2007-05-11
US7691822B2 (en) 2010-04-06
US20240000968A1 (en) 2024-01-04
EP2301584A1 (en) 2011-03-30
EP1691844A4 (en) 2007-11-28
US20190374654A1 (en) 2019-12-12
KR20060127397A (ko) 2006-12-12
JP2011148834A (ja) 2011-08-04
US20210322572A1 (en) 2021-10-21
EP1691844B1 (en) 2011-03-23
CA2548100C (en) 2015-03-24
US20160045618A1 (en) 2016-02-18
SG166117A1 (en) 2010-11-29
DE602004031973D1 (de) 2011-05-05
US20100266547A1 (en) 2010-10-21
KR101163248B1 (ko) 2012-07-05
CN1893981A (zh) 2007-01-10
JP2007513963A (ja) 2007-05-31
CN1893981B (zh) 2011-03-23

Similar Documents

Publication Publication Date Title
NO20062385L (no) Preparat for behandling av interferonresistente tumorer
CY1111237T1 (el) Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης
ATE465181T1 (de) Humanisierte anti-cmet-antagonisten
ATE551048T1 (de) Proteinhydrolysate enthaltende kosmetische zusammensetzungen
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
MX341370B (es) Antagonistas anti - beta7 humanizados y usos para los mismos.
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
HK1088840A1 (en) Stable analogs of glp-1 glp-1
DE60313859D1 (de) Induktion der anti-tumor-ctl-immunität durch in-vivo-aktivierung von 4-1bb und/oder cd40
PL1718677T3 (pl) Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze
MY142044A (en) Endoparasiticidal compositions for topical application
UY28641A1 (es) Anticuerpos
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
WO2002060951A3 (en) Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
EA201100071A1 (ru) Новые композиции и способы
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
WO2005016132A3 (en) Diagnostics for sars virus
ATE308335T1 (de) Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese
WO2003066660A3 (en) A PAIR OF ANTIBODY Fv FRAGMENTS STABILIZED BY COILED­COIL PEPTIDES
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
WO2005023992A3 (en) Compositions and methods for inhibiting white spot syndrome virus (wssv) infection
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe
CY1108280T1 (el) Basb205 πολυπεπτιδια και πολυνουκλεοτιδια που τα κωδικοποιουν
ATE312921T1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
ATE554102T1 (de) Therapeutische verwendungen von monoklonalen antikörpern gegen den angiotensin-ii typ-1 rezeptor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application